TrialSignal
Clinical trial intelligence report
Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02682693
Status
COMPLETED
Phase
Phase 2
Sponsor
GBG Forschungs GmbH
Executive brief
Investment-Ready Snapshot
The GeparX trial investigated denosumab as an adjunct to neoadjuvant chemotherapy in patients with RANK-positive breast cancer. Conducted by GBG Forschungs GmbH in collaboration with Amgen and Celgene, the study aimed to enhance pathological complete response (pCR) rates and improve patient outcomes. The trial enrolled 780 participants and was completed in December 2020.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02682693
Indication
Breast Cancer Female NOS
Modality
monoclonal antibody
Target
RANK-positive or RANK-negative Primary Breast Cancer
Intervention
Denosumab, nab-Paclitaxel, Epirubicin, Cyclophosphamide, Carboplatin, Trastuzumab, Pertuzumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.